Literature DB >> 19167980

beta2 Adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury.

James Rough1, Ryan Engdahl, Kay Opperman, Smitha Yerrum, M Alexandra Monroy, John M Daly.   

Abstract

BACKGROUND: Major operative injury initiates immunologic changes that may result in a systemic inflammatory response, leading to organ dysfunction/sepsis. Catecholamines seem to be key mediators. The effects of beta(2) receptor blockade in vitro and in vivo before and after operative injury were studied to clarify their role.
METHODS: In vitro studies were done in RAW 264.7 cells using epinephrine (50 micromol/L) with or without alpha(2)- and beta(2)-receptor blockade. Comparative gene expression analysis on the Toll-like receptor (TLR)-4 receptor signaling pathway was performed between RAW cells pretreated with epinephrine with subsequent lipopolysaccharide (LPS) stimulation versus LPS alone. Confirmatory studies were performed by real-time reverse transcription polymerase chain reaction (RT-PCR). Tumor necrosis factor (TNF)-alpha gene and protein expression were determined via real time RT-PCR and enzyme-linked immunosorbent assay, respectively. In vivo, Balb/C mice received no treatment nor injury (group I). Group II received operative injury and vehicle injection, group III received ICI 118,551 (beta(2)-receptor antagonist) 30 minutes before or in separate studies after operative injury. At 7 days, splenic macrophages were harvested and cytokine production was measured with or without LPS. In separate experiments, cecal ligation and puncture (CLP) was done 7 days after operation and survival determined.
RESULTS: In vitro studies demonstrated that epinephrine pretreatment significantly increased TNF-alpha production with LPS stimulation (P < .05). beta(2)-Receptor blockade significantly attenuated (P < .05) LPS stimulated TNF-alpha production. MD-2, an essential coactivator of TLR-4 signaling, gene expression was significantly elevated when cells were pretreated with epinephrine before LPS exposure (P < .001). In vivo studies demonstrated a significant decrease (P < .05) in TNF-alpha and interleukin-6 production in the ICI 118,551 group. Similar findings were demonstrated measuring monocyte chemoattractant protein-1 and interferon-gamma cytokine levels (P < .05) versus no treatment. ICI 118,551 treatment 30 minutes before operation demonstrated a 31% reduction in mortality after CLP (P < .05).
CONCLUSION: This study demonstrates that beta(2)-receptor blockade reduces macrophage cytokine production and improves survival showing the critical importance of catecholamines to the immunologic response in surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167980     DOI: 10.1016/j.surg.2008.09.013

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healing.

Authors:  Mohan R Dasu; Sandra R Ramirez; Thi Dinh La; Farzam Gorouhi; Chuong Nguyen; Benjamin R Lin; Chelcy Mashburn; Heather Stewart; Thomas R Peavy; Jan A Nolta; Roslyn R Isseroff
Journal:  Stem Cells Transl Med       Date:  2014-04-23       Impact factor: 6.940

Review 2.  β-Blockade use for Traumatic Injuries and Immunomodulation: A Review of Proposed Mechanisms and Clinical Evidence.

Authors:  Tyler J Loftus; Philip A Efron; Lyle L Moldawer; Alicia M Mohr
Journal:  Shock       Date:  2016-10       Impact factor: 3.454

3.  The Relationship Between Severe Complications, Beta-Blocker Therapy and Long-Term Survival Following Emergency Surgery for Colon Cancer.

Authors:  Rebecka Ahl; Peter Matthiessen; Yang Cao; Gabriel Sjolin; Olle Ljungqvist; Shahin Mohseni
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

4.  β-adrenergic blockade is associated with a reduced risk of 90-day mortality after surgery for hip fractures.

Authors:  Ahmad Mohammad Ismail; Tomas Borg; Gabriel Sjolin; Arvid Pourlotfi; Sebastian Holm; Yang Cao; Per Wretenberg; Rebecka Ahl; Shahin Mohseni
Journal:  Trauma Surg Acute Care Open       Date:  2020-07-29

Review 5.  Sepsis-induced cardiomyopathy.

Authors:  Francisco J Romero-Bermejo; Manuel Ruiz-Bailen; Julian Gil-Cebrian; Maria J Huertos-Ranchal
Journal:  Curr Cardiol Rev       Date:  2011-08

6.  β2AR antagonists and β2AR gene deletion both promote skin wound repair processes.

Authors:  Christine E Pullar; Gabrielle S Le Provost; Andrew P O'Leary; Sian E Evans; Brian S Baier; R Rivkah Isseroff
Journal:  J Invest Dermatol       Date:  2012-04-12       Impact factor: 8.551

7.  Catecholamine stress alters neutrophil trafficking and impairs wound healing by β2-adrenergic receptor-mediated upregulation of IL-6.

Authors:  Min-Ho Kim; Farzam Gorouhi; Sandra Ramirez; Jennifer L Granick; Barbara A Byrne; Athena M Soulika; Scott I Simon; R Rivkah Isseroff
Journal:  J Invest Dermatol       Date:  2013-10-11       Impact factor: 8.551

8.  Effects of beta-blocker therapy on mortality after elective colon cancer surgery: a Swedish nationwide cohort study.

Authors:  Rebecka Ahl; Peter Matthiessen; Gabriel Sjölin; Yang Cao; Göran Wallin; Olle Ljungqvist; Shahin Mohseni
Journal:  BMJ Open       Date:  2020-07-07       Impact factor: 2.692

9.  Mice lacking the β2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia.

Authors:  Robin E White; Curtis Palm; Lijun Xu; Evelyn Ling; Mitchell Ginsburg; Bernie J Daigle; Ruquan Han; Andrew Patterson; Russ B Altman; Rona G Giffard
Journal:  ASN Neuro       Date:  2012-09-07       Impact factor: 4.146

10.  Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury.

Authors:  Alex P Di Battista; Shawn G Rhind; Michael G Hutchison; Syed Hassan; Maria Y Shiu; Kenji Inaba; Jane Topolovec-Vranic; Antonio Capone Neto; Sandro B Rizoli; Andrew J Baker
Journal:  J Neuroinflammation       Date:  2016-02-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.